Trials / Active Not Recruiting
Active Not RecruitingNCT07116889
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
A Phase 1 First in Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GB-0895 in Adults With Mild to Moderate Asthma or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- Sponsor
- Generate Biomedicines · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GB-0895 (SC) | Single subcutaneous dose of GB-0895 |
| BIOLOGICAL | GB-0895 (SC) | Multiple subcutaneous doses of GB-0895 |
| DRUG | Placebo (SC) | Single subcutaneous dose of placebo |
| DRUG | Placebo (SC) | Multiple subcutaneous doses of placebo |
Timeline
- Start date
- 2023-12-12
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2025-08-12
- Last updated
- 2025-11-05
Locations
13 sites across 3 countries: United States, Germany, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07116889. Inclusion in this directory is not an endorsement.